Deciphera Pharmaceuticals, Inc. - Common Stock (NQ:DCPH)

25.59 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Deciphera Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results

May 03, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Preview: Deciphera Pharmaceuticals's Earnings ↗

May 02, 2023

Via Benzinga

Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023

April 26, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days

April 19, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Where Deciphera Pharmaceuticals Stands With Analysts ↗

March 15, 2023

Via Benzinga

Looking Into Deciphera Pharmaceuticals's Return On Capital Employed ↗

February 08, 2023

Via Benzinga

Earnings Outlook For Deciphera Pharmaceuticals ↗

February 06, 2023

Via Benzinga

The Latest Analyst Ratings for Deciphera Pharmaceuticals ↗

January 25, 2023

Via Benzinga

Why Deciphera Pharmaceuticals Stock Jumped This Week ↗

March 16, 2023

The company's lead therapy received an FDA Breakthrough Therapy designation.

Via The Motley Fool

Stifel Is Bullish On This 'Competitive Late-Comer' In Gastric Cancer Space ↗

March 16, 2023

Via Benzinga

Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18

March 14, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023

March 14, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT

March 01, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

February 27, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Top 5 Health Care Stocks That May Rocket Higher In Q1 2023 ↗

February 27, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results

February 07, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

February 02, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023

January 31, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying ↗

January 25, 2023

Although US stocks closed mixed on Tuesday, there were a few notable insider trades.

Via Benzinga

Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

January 24, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

January 24, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

January 19, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low ↗

January 19, 2023

U.S. stocks traded lower this morning, with the Dow Jones dropping around 200 points on Thursday.

Via Benzinga

Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 19, 2023

Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force.

Via Benzinga

Why Deciphera Pharmaceuticals Stock Is Nosediving ↗

January 19, 2023

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) shares are trading lower by 10.48% to $18.45 Thursday morning after the company announced a $125 million proposed public offering of common stock.

Via Benzinga

Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket ↗

January 19, 2023

Gainers Tricida, Inc. (NASDAQ: TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday.

Via Benzinga

Alcoa, H.B. Fuller And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

January 19, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock

January 18, 2023

From Deciphera Pharmaceuticals, Inc.

Via Business Wire

Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 04, 2023

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗

January 06, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.